Myovant & Pfizer: Long-term Study Supports Potential Benefit Of Relugolix Combination Therapy

Myovant Sciences (MYOV) and Pfizer Inc. (PFE) reported positive data from the phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy in women with uterine fibroids. The data showed the potential value of continued treatment for women with uterine fibroids, with those receiving relugolix combination therapy in the study experiencing meaningful symptom relief for up to two years.

The study met its primary endpoint with 78.4% of women who continued on relugolix combination therapy achieving the sustained responder rate through week 76 compared with 15.1% of women who discontinued treatment and initiated placebo at week 52. All three key secondary endpoints in the study were also achieved.

Relugolix combination tablet is under review by the FDA for the treatment of women with uterine fibroids, with a decision anticipated by June 1, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sturtevant, Wisconsin-based BRP U.S. Inc. is recalling around 20 models of Side-by-Side vehicles citing fire risk, the U.S. Consumer Product Safety Commission. The recall involves about 34,400 units of Model Years 2020 and 2021 Can-AM Defender HD10 side-by-side vehicles. While reporting financial results for the second quarter on Friday, technology company Honeywell international Inc. (HON) raised its adjusted earnings and sales guidance for the full-year 2021, based on the second-quarter performance and management's outlook for the remainder of the year. For fiscal... Shares of Vodafone Group Plc were gaining around 2 percent in the morning trading in London after the British telecom major reported higher revenues in its first quarter. Looking ahead, the company said it is on track to deliver fiscal year 2022 guidance, with Adjusted EBITDAaL expected to be between 15.0 billion euros - 15.4 billion euros and Adjusted free cash flow of at least 5.2 billion euros
Follow RTT